Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK, Novartis Downplay Pfizer/Pharmacia: New Themes For “Critical Mass”?

Executive Summary

The Pfizer/Pharmacia merger will not fundamentally change the pharmaceutical industry dynamics unless Pfizer sheds product lines to concentrate greater resources behind key brands, Novartis and GSK argued in separate investor presentations
Advertisement

Related Content

Pfizer/Pharmacia Flexes Market Strength: More Bulk For Medicaid/Medicare
Pfizer/Pharmacia Flexes Market Strength: More Bulk For Medicaid/Medicare
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Advertisement
UsernamePublicRestriction

Register

PS040227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel